NCT01564706已完成1 期
Positron Emission Tomography Whole Body Biodistribution Using 18F-AV-45
Avid Radiopharmaceuticals1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Whole Body Radiation Dosimetry
研究概览
简要总结
This study will determine how florbetapir F 18 (18F-AV-45) radioactivity is distributed throughout the body.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able to lie still on the imaging table for periods up to 1 hour
排除标准
- •Radiation exposure for experimental purposes within the last year
- •Claustrophobic or otherwise unable to tolerate the imaging procedure
- •Medical condition or surgical history that would confound evaluation
- •Current clinically significant cardiovascular disease
- •Received an investigational medication within the last 30 days
研究组 & 干预措施
Healthy Volunteers
Experimental
Healthy male or female subjects, between 18 and 85 years of age.
干预措施: florbetapir F 18 (Drug)
结局指标
主要结局
Whole Body Radiation Dosimetry
时间窗: 0-380 min after injection
Radiation dose values (millisieverts/megabecquerel \[mSv/MBq\]) for regions of the whole body. Target organs included the adrenals, brain, breasts, gall bladder wall, lower large intestine wall, small intestine wall, stomach wall, upper large intestine wall, heart wall, kidneys, liver, lungs, muscle, ovaries, pancreas, osteogenic cells, skin, spleen, testes, thymus, thyroid, urinary bladder wall, uterus, and total body.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Florbetapir (18F) in Japanese Healthy VolunteersAlzheimer's DiseaseNCT01660815Avid Radiopharmaceuticals7
已完成
不适用
Study to Calculate the Radiation Dosimetry in Subjects With Head and Neck CancerHead and Neck CancerNCT00245349University of Iowa9
已完成
1 期
Use of [18F]FECNT in Positron Emission TomographyHealthyNCT00083629National Institute of Mental Health (NIMH)30
已完成
不适用
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory DiseasesInflammationCancerNCT01180907Jonsson Comprehensive Cancer Center10
Unknown
不适用
Dynamic Whole Body Positron Emission Tomography/Computed Tomography ImagingNeuroendocrine TumorsCarcinoid TumorProstate CancerParagangliomaNeuroblastomaProstatic NeoplasmsNCT04017104British Columbia Cancer Agency60